small molecule

OPVEE

NALMEFENE HYDROCHLORIDE

Loss of exclusivityAugust 2042latest FDA-listed patent expiry

CompanyIndivior →See this company's full patent-cliff portfolio

Drug detail

Brand name	OPVEE
Active ingredient	NALMEFENE HYDROCHLORIDE
Strength	EQ 2.7MG BASE/SPRAY
Dosage form	SPRAY
Route	NASAL
Modality	Small molecule
FDA approval	May 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
12290596	August 2042	use U-4182
11458091	July 2038	product

Regulatory exclusivity

Code	Expires
NP	May 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Indivior